• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Monogram Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    7/22/24 5:19:32 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care
    Get the next $MGRM alert in real time by email
    false 0001769759 0001769759 2024-07-22 2024-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): July 22, 2024

     

    Monogram Technologies Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41707   81-3777260
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification Number)

     

    3919 Todd Lane, Austin, TX 78744

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (512) 399-2656

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Common Stock, par value $0.001 per share   MGRM   The Nasdaq Stock Market

      

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

    ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

     

    On July 22, 2024, Monogram Technologies Inc. (“we,” “us,” “our”), entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. to sell shares of our common stock from time to time through an “at-the-market” equity offering program under which B. Riley Securities, Inc. will act as our sales agent (the “Sales Agent”).

     

    Under the Sales Agreement, we will set the parameters for the sale of shares of our common stock, including the maximum number or amount of shares to be sold, the time period during which sales may be made, any limitation on the number or amount of shares that may be sold in any one trading day, and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, the Sales Agent may sell shares of our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on or through the Nasdaq Capital Market (“Nasdaq”), on or through any other existing trading market for our common stock or to or through a market maker. The Sales Agent will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of Nasdaq. We made certain customary representations, warranties and covenants to the Sales Agent in the Sales Agreement, and we agreed to customary indemnification and contribution obligations, including with respect to liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. The Sales Agreement may be terminated by us or the Sales Agent for any or no reason upon five days’ prior notice.

     

    Under the Sales Agreement, we may issue and sell from time to time shares of our common stock. We have no obligation to sell any shares of our common stock under the Sales Agreement, and we may suspend solicitation and offers under the Sales Agreement for any reason in our sole discretion. We agreed to pay the Sales Agent a commission equal to up to 3.0% of the gross proceeds from the sales of shares of our common stock pursuant to the Sales Agreement or such lower amount as we and the Sales Agent may agree.

     

    Any shares of our common stock sold under the Sales Agreement will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-279927) (the “Registration Statement”), and the base prospectus included therein, originally filed with the U.S. Securities and Exchange Commission (“SEC”) on June 4, 2024 and declared effective by the SEC on June 14, 2024. A prospectus supplement relating to the offering of shares of our common stock under the Sales Agreement was filed with the SEC on July 22, 2024.

     

    The foregoing description of terms and conditions of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The provisions of the Sales Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to the Sales Agreement and are not intended as documents for investors and the public to obtain factual information about our current state of affairs. For such information, investors and the public should look to the disclosures contained in our reports to and other filings with the SEC.

     

    The legal opinion of Duane Morris LLP relating to the shares of our common stock that may be offered and sold pursuant to the Registration Statement and the Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

     

     

     

     

    ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

     

      (d) Exhibits:

     

    Exhibit No.    Description
         
    1.1   At Market Issuance Sales Agreement, dated July 22, 2024, between B. Riley Securities, Inc. and Monogram Technologies Inc.
    5.1   Opinion of Duane Morris LLP
    23.1   Consent of Duane Morris LLP (included in Exhibit 5.1)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      MONOGRAM TECHNOLOGIES INC.
       
    Dated: July 22, 2024 /s/ Benjamin Sexson
      Benjamin Sexson
      Chief Executive Officer

     

    4 

     

    Get the next $MGRM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGRM

    DatePrice TargetRatingAnalyst
    12/9/2024$4.00Buy
    ROTH MKM
    More analyst ratings

    $MGRM
    SEC Filings

    View All

    SEC Form EFFECT filed by Monogram Technologies Inc.

    EFFECT - Monogram Technologies Inc. (0001769759) (Filer)

    11/20/25 12:15:11 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Monogram Technologies Inc.

    EFFECT - Monogram Technologies Inc. (0001769759) (Filer)

    11/20/25 12:15:14 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12G filed by Monogram Technologies Inc.

    15-12G - Monogram Technologies Inc. (0001769759) (Filer)

    10/21/25 11:59:09 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Announces World's First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery

    The Procedure Utilized Monogram's mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World's First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based robotic knee replacement procedure on a live patient. The procedure was performed at the Krishna Shalby Hospital in Ahmedabad India, as part of Monogram's multi-center clin

    7/29/25 9:30:05 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 22, 2025 /PRNewswire/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation o

    7/22/25 9:15:00 AM ET
    $AGEN
    $CLOV
    $MGRM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Medical/Dental Instruments

    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Monogram Technologies with a new price target

    ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

    12/9/24 7:59:36 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Gray Colleen

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:59:13 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Gray Colleen

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:58:09 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Gray Colleen

    3 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:57:01 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Leadership Updates

    Live Leadership Updates

    View All

    Monogram Accepted to NVIDIA Inception Program

    Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co

    4/11/24 1:20:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Reports First Quarter 2025 Financial Results

    Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

    5/14/25 4:01:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

    AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can b

    11/12/24 8:31:00 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care